NASDAQ:CRDF Cardiff Oncology (CRDF) Stock Price, News & Analysis $2.99 +0.16 (+5.65%) (As of 10/28/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About Cardiff Oncology Stock (NASDAQ:CRDF) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Cardiff Oncology alerts:Sign Up Key Stats Today's Range$2.88▼$3.1250-Day Range$2.11▼$2.9952-Week Range$0.94▼$6.42Volume689,797 shsAverage Volume927,741 shsMarket Capitalization$139.18 millionP/E RatioN/ADividend YieldN/APrice Target$9.67Consensus RatingBuy Company OverviewCardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.Read More… Tim Sykes’ Urgent Trade Alert: “Make this move now” (Ad)WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT about Trump or Biden dropping out of the race…Click here to see a unique election-year trade Cardiff Oncology Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks26th Percentile Overall ScoreCRDF MarketRank™: Cardiff Oncology scored higher than 26% of companies evaluated by MarketBeat, and ranked 905th out of 997 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingCardiff Oncology has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageCardiff Oncology has only been the subject of 1 research reports in the past 90 days.Read more about Cardiff Oncology's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Cardiff Oncology are expected to decrease in the coming year, from ($1.00) to ($1.05) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cardiff Oncology is -3.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cardiff Oncology is -3.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCardiff Oncology has a P/B Ratio of 1.92. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Cardiff Oncology's valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted15.73% of the outstanding shares of Cardiff Oncology have been sold short.Short Interest Ratio / Days to CoverCardiff Oncology has a short interest ratio ("days to cover") of 14.8, which indicates bearish sentiment.Change versus previous monthShort interest in Cardiff Oncology has recently increased by 7.17%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCardiff Oncology does not currently pay a dividend.Dividend GrowthCardiff Oncology does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted15.73% of the outstanding shares of Cardiff Oncology have been sold short.Short Interest Ratio / Days to CoverCardiff Oncology has a short interest ratio ("days to cover") of 14.8, which indicates bearish sentiment.Change versus previous monthShort interest in Cardiff Oncology has recently increased by 7.17%, indicating that investor sentiment is decreasing significantly. News and Social Media3.0 / 5News Sentiment0.44 News SentimentCardiff Oncology has a news sentiment score of 0.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.68 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Cardiff Oncology this week, compared to 1 article on an average week.Search Interest9 people have searched for CRDF on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.MarketBeat Follows1 people have added Cardiff Oncology to their MarketBeat watchlist in the last 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Cardiff Oncology insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.60% of the stock of Cardiff Oncology is held by insiders.Percentage Held by InstitutionsOnly 16.29% of the stock of Cardiff Oncology is held by institutions.Read more about Cardiff Oncology's insider trading history. Receive CRDF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cardiff Oncology and its competitors with MarketBeat's FREE daily newsletter. Email Address CRDF Stock News HeadlinesCardiff Oncology Inc (CRDF) Q2 2024 Earnings Call Highlights: Strategic Trials and Financial ...October 9, 2024 | finance.yahoo.comCraig-Hallum Initiates Coverage of Cardiff Oncology (CRDF) with Buy RecommendationSeptember 6, 2024 | msn.com24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast world of passive crypto income, where you set up a dependable income stream that works for you, whether you're at your computer or living your life.October 29, 2024 | Crypto Swap Profits (Ad)Earnings call: Cardiff Oncology Q2 2024 update on CRDF-004 trial and financesAugust 15, 2024 | uk.investing.comCardiff Oncology, Inc. (CRDF) Q2 2024 Earnings Call TranscriptAugust 13, 2024 | seekingalpha.comWhat Wall Street expects from Cardiff Oncology's earningsAugust 7, 2024 | markets.businessinsider.comCompanies Like Cardiff Oncology (NASDAQ:CRDF) Are In A Position To Invest In GrowthJuly 24, 2024 | finance.yahoo.comCardiff Oncology to Present at the Jefferies Healthcare ConferenceMay 29, 2024 | globenewswire.comSee More Headlines CRDF Stock Analysis - Frequently Asked Questions How have CRDF shares performed this year? Cardiff Oncology's stock was trading at $1.48 at the start of the year. Since then, CRDF shares have increased by 102.0% and is now trading at $2.99. View the best growth stocks for 2024 here. How were Cardiff Oncology's earnings last quarter? Cardiff Oncology, Inc. (NASDAQ:CRDF) posted its quarterly earnings results on Thursday, August, 8th. The company reported ($0.26) earnings per share for the quarter, missing analysts' consensus estimates of ($0.25) by $0.01. The company had revenue of $0.16 million for the quarter, compared to analysts' expectations of $0.12 million. Cardiff Oncology had a negative trailing twelve-month return on equity of 62.65% and a negative net margin of 6,143.91%. Who are Cardiff Oncology's major shareholders? Top institutional shareholders of Cardiff Oncology include Assenagon Asset Management S.A. (0.60%) and SG Americas Securities LLC (0.05%). Insiders that own company stock include Gary W Pace, Lale White, James E Levine and Mark Erlander. View institutional ownership trends. How do I buy shares of Cardiff Oncology? Shares of CRDF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Cardiff Oncology own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cardiff Oncology investors own include Block (SQ), NVIDIA (NVDA), CrowdStrike (CRWD), Palantir Technologies (PLTR), Digital Turbine (APPS), Meta Platforms (META) and Advanced Micro Devices (AMD). Company Calendar Last Earnings8/08/2024Today10/28/2024Next Earnings (Estimated)11/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CRDF CUSIPN/A CIK1213037 Webcardiffoncology.com Phone(858) 952-7570FaxN/AEmployees20Year Founded1999Price Target and Rating Average Stock Price Target$9.67 High Stock Price Target$14.00 Low Stock Price Target$7.00 Potential Upside/Downside+223.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.91) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-41,440,000.00 Net Margins-6,143.91% Pretax Margin-6,143.91% Return on Equity-62.65% Return on Assets-52.69% Debt Debt-to-Equity RatioN/A Current Ratio4.97 Quick Ratio4.97 Sales & Book Value Annual Sales$490,000.00 Price / Sales284.05 Cash FlowN/A Price / Cash FlowN/A Book Value$1.56 per share Price / Book1.92Miscellaneous Outstanding Shares46,550,000Free Float43,012,000Market Cap$139.18 million OptionableOptionable Beta1.96 Social Links 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report This page (NASDAQ:CRDF) was last updated on 10/29/2024 by MarketBeat.com Staff From Our Partnerstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredElon Musk Drops Stunning Bombshell?Elon Musk just dropped a BOMBSHELL that could send shockwaves throughout the tech industry… While deliverin...Paradigm Press | SponsoredTrump or Kamala? It may come down to this strange twist…Could this be the key to America's second coming? A strange resurrection born in the hollers of Appalachia? ...Porter & Company | SponsoredGold at $2,600... But This Stock Gives You More for Under $20Gold just soared over $2,600 an ounce. But what if I told you there's a way to get exposure to MORE than an...Monument Traders Alliance | Sponsored625,000% GainThe recent pullback in the crypto markets has left many investors in full-on panic mode, convinced the bull ru...Crypto Swap Profits | Sponsored“Buffett Indicator” Predicts 62% Stock Market CrashThe last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cardiff Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cardiff Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.